Citi Catalyst Pharmaceutical (CPRX): 'Firdapse Patent Litigation Settlement with Teva Meaningfully Derisks LOE Overhang on Shares'
Tweet Send to a Friend
Citi analyst Samantha Semenkow reiterated a Buy rating and $31.00 price target on Catalyst Pharmaceutical Partners (NASDAQ: CPRX)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
